Author Archive: Tracy Cooley

Tracy Cooley

Tracy serves as the Director of Events Communications and handles all communications for BIO’s events and emerging company policy issues. She loves blogging and podcasting on all things biotech and believes in the great potential of the industry, looking for every opportunity to spread the message far and wide. Nearly everyone in her family is a golfer, and as such, she has what many people have called a “natural” swing. Sometimes she even hits the ball. Tracy just finished her ninth marathon, and has nearly mastered the skill of one-foot-in-front-of-the-other (usually, sometimes the laces get in the way). The joy of her life is her five-year-old daughter Josephine.

Latest Posts

Long-term immune response for Vical’s TransVax™ vaccine in Phase 2 trial

Vical Incorporated (Nasdaq:VICL) announced that TransVax™ cytomegalovirus vaccine continued to demonstrate an overall increase in cellular immune responses compared with placebo at the seven-month immunogenicity data point in an ongoing Phase 2 trial.

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Inovio reports clinical trial progress of cervical cancer vaccine

Inovio Biomedical Corporation (NYSE Amex: INO) announced safety and immunogenicity data from its therapeutic cervical cancer vaccine (VGX-3100) trial. VGX-3100 is a DNA vaccine targeting the E6 and E7 proteins of human papillomavirus types 16 and 18 and is delivered via in vivo electroporation. The vaccine was found to be generally safe and well tolerated, and achieved significant cellular and humoral immune responses at the lowest dose administered. Read the release.

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Immunovaccine begins trading as “IMV”

Immunovaccine Inc. (TSX-V:IMV) will begin trading on the TSX-Venture Exchange as a Tier 1 issuer under the ticker symbol “IMV”. Immunovaccine Inc. also announces the closing of the previously announced private placement totaling $8,269,109 in gross proceeds. The TSX Venture Exchange has accepted the private placement for filing.  Read the release.

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Oncolytics enters into agreement with FDA for Phase 3 trial of REOLYSIN®

Oncolytics Biotech Inc. (“Oncolytics”) (TSX:ONC, NASDAQ:ONCY) has reached an agreement with the FDA under the Special Protocol Assessment (SPA) process for the design of a Phase 3 trial examining REOLYSIN in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers. The SPA is an agreement between Oncolytics and the FDA that the design and planned analyses of the Phase 3 study is adequately designed to provide the necessary data, that depending Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Medicago begins human testing of flu vaccine

Medicago Inc. (TSX-V: MDG) announced a Phase I trial for its H5N1 Avian Influenza vaccine. The Phase I study will evaluate safety, tolerability and the immune response of the Company’s H5N1 vaccine candidate in 48 healthy volunteers between the ages 18 to 60. Results of the study are expected during the fourth quarter of 2009. Read the release.

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,